A specialty chemicals micro-cap with a 66-product portfolio, one factory, and 24 employees goes public on NSE SME Emerge
Biopol Chemicals Ltd. traces its roots to United Chemical Company, a specialty chemicals trading business run by Santanu Sarkar out of West Bengal.
In April 2023, the father-son duo incorporated Biopol Chemicals Ltd. in Ahmedabad, Gujarat, and folded United Chemical Company’s operations — the clients, the product lines, the supplier relationships — into the new corporate entity.
The company issued its initial equity at par value. In November 2023 and January 2024, additional shares were placed at Rs 800 per share. A 71-for-1 bonus issue followed in January 2024, reshaping the capital table. By May 2024, Biopol had converted into a public limited company. By early 2026, it had set up manufacturing, built a 66-product portfolio, obtained ISO and ZDHC Level 3 certifications
What the Company Does
BCL manufactures, trades, and distributes specialty chemicals across four categories: silicones (40 products), biochemicals (15), polyelectrolytes (6), and emulsifiers (5) — totalling 66 products. These are industrial-grade inputs used in textile processing, home care formulations, agricultural applications, and industrial manufacturing. The company also offers technical consultancy services to clients on the application of specialty chemicals in textile processing, dye manufacturing, and industrial formulations.
The business is entirely B2B, serving institutional buyers through direct sales and distributors. Domestic revenue is concentrated in West Bengal and Gujarat, with additional presence in Maharashtra, Tamil Nadu, and Karnataka. Bangladesh is the sole export market.
BCL operates from a single manufacturing unit in West Bengal with an installed capacity of 18.25 lakh litres per annum. As of December 31, 2025, the company had 24 employees and a confirmed order book of Rs 13.31 crore. The company holds ISO certification and ZDHC Level 3 accreditation across 42 products.
The Industry
India’s specialty chemicals sector has been growing at 9-10% CAGR, supported by the China+1 sourcing trend, expanding domestic manufacturing, and rising demand from textiles, agriculture, and consumer goods. Silicone-based specialty chemicals — BCL’s primary product line — have seen broadening applications across industries. Bangladesh, BCL’s export market, is the world’s second-largest apparel exporter and a significant consumer of textile processing chemicals.
Operating Parameters
BCL’s topline has scaled rapidly over a short period. Revenue went from Rs 17.43 crore in FY23 to Rs 25.47 crore in FY24 — a jump of 46%. It then nearly doubled to Rs 49.15 crore in FY25. In the first nine months of FY26 alone, the company clocked Rs 48.97 crore, which matches the entire previous year’s revenue with a quarter still to go.
Profitability has followed a similar curve. Net profit rose from Rs 1.28 crore in FY23 to Rs 2.96 crore in FY24 and Rs 4.33 crore in FY25. The nine-month FY26 figure of Rs 6.00 crore has already surpassed the full-year FY25 number.
PAT margins have improved materially — from 2.72% in FY23 to 12.29% in the first nine months of FY26 — suggesting a shift in revenue mix, better pricing power, or operating leverage as volumes scaled. Return on capital employed has stayed in a band ranging from 17.83% in FY23 to a peak of 34.03% in FY24, coming in at 26.32% for the nine-month FY26 period.
On the manufacturing side, capacity utilisation has been high. The West Bengal plant ran at 93.59% in FY25 and 87.27% (adjusted for a nine-month period) in the current fiscal year — indicating that the existing facility is running near its ceiling, which partly explains why Rs 12.26 crore of the IPO proceeds is earmarked for acquiring new industrial land.
The three-year average EPS stands at Rs 4.91 and average return on net worth across reported periods is 31.63%.
One important caveat on all of these numbers: FY23 is reported on a standalone basis, while FY24 onward is consolidated — reflecting the absorption of United Chemical Company’s operations.
The IPO
This is a book-built issue — the final price is determined through investor bidding within a price band, as opposed to a fixed-price issue where all applicants pay the same predetermined price. The price band is Rs 102 to Rs 108 per share.
It is a 100% fresh issue of 28,94,400 equity shares at a face value of Rs 10 each. There is no offer for sale — promoters are not selling existing shares. All proceeds go to the company.
| Parameter | Detail |
|---|---|
| Issue type | Book-built, 100% fresh issue |
| Shares offered | 28,94,400 (Rs 10 face value) |
| Price band | Rs 102 – Rs 108 |
| Issue size (upper band) | Rs 31.26 crore |
| Minimum retail application | 2,400 shares / Rs 2,59,200 |
| Minimum HNI application | 3,600 shares / Rs 3,88,800 |
| Post-IPO market cap | Rs 116.70 crore |
| Equity dilution | 26.79% |
| Pre-IPO paid-up capital | Rs 7.91 crore |
| Post-IPO paid-up capital | Rs 10.81 crore |
| Listing platform | NSE SME Emerge |
| Open – Close | Feb 6 – Feb 10, 2026 |
| Allotment (tentative) | Feb 11, 2026 |
| Listing (tentative) | Feb 13, 2026 |
| Lead manager | Smart Horizon Capital Advisors |
| Registrar | Bigshare Services |
| Market maker | Shreni Shares Ltd. |
Use of Proceeds
| Purpose | Amount (Rs Cr) |
|---|---|
| Acquisition of industrial land | 12.26 |
| Repayment/prepayment of borrowings | 11.10 |
| General corporate purposes | ~7.90 |
| Total | ~31.26 |
The largest allocation is toward land acquisition for future capacity expansion — the current plant is running above 90% utilisation. About a third goes to reducing existing debt with the remainder for working capital and operational needs.
Financial Performance
| Period | Total Income (Rs Cr) | Net Profit (Rs Cr) | PAT Margin | RoCE |
|---|---|---|---|---|
| FY23 (Standalone) | 17.43 | 1.28 | 2.72% | 17.83% |
| FY24 (Consolidated) | 25.47 | 2.96 | 11.63% | 34.03% |
| FY25 (Consolidated) | 49.15 | 4.33 | 8.81% | 30.57% |
| 9M FY26 (Consolidated) | 48.97 | 6.00 | 12.29% | 26.32% |
Capital History
Promoters initially subscribed to equity at par (Rs 10). Further shares were issued at Rs 800 per share in November 2023 and January 2024. A bonus issue of 71 shares for every 1 held was made in January 2024. The promoters’ average cost of acquisition works out to Rs 4.73 and Rs 11.11 per share. The IPO offers shares to the public at Rs 102–108.
Valuation
At the upper band of Rs 108, the price-to-book value is 4.37x based on a NAV of Rs 24.69 per share as of December 31, 2025. Post-IPO NAV has not been disclosed in the offer document.
The P/E ratio works out to 26.93x on FY25 earnings, and 14.57x on annualized nine-month FY26 earnings.
The offer document lists Rossari Biotech (P/E 21.5x), Fineotex Chemical (25.7x), and Indian Emulsifiers (8.74x) as listed peers — though these companies differ significantly in scale, operating history, and market capitalization.
Smart Horizon Capital Advisors has managed 20 IPOs in the last two fiscal years.
Risk Factors
The company was incorporated less than three years ago. The entire financial track record is short, with a mid-stream shift from standalone to consolidated reporting. Operations are concentrated in a single manufacturing unit with 24 employees. Revenue is geographically concentrated in West Bengal and Gujarat domestically, and dependent on Bangladesh for exports — a market facing political and economic instability. The textile sector, a key end market, is cyclical. Raw material costs are subject to volatility. The sharp acceleration in revenue and margins in the pre-IPO period is a notable feature of the financials. Post-IPO NAV is not disclosed. The company has not paid dividends in any reported period
